Market Overview

UPDATE: Stifel Nicolaus Initiates Coverage on Illumina, Inc. at Buy, Announces $200.00 PT

Share:

In a report published Tuesday morning, Stifel analyst Miroslava Minkova initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating and $200 price target.

Minkova cited the company's dominant position (>70%) in the Next Generation Sequencing (NGS) market (high potential for growth) and other drivers.

Other favorable factors include a strong near-term and long-term growth outlook, when compared to other mid to large companies in the industry. NGS is slowly becoming the standard for use by genomic analysis applications, and expected industry growth could sustain the company's valuation. There should be more than $20 Billion in opportunities for the use of NGS in different niches in the healthcare industry, including diagnostics, prenatal screening, and immunogenetics: other factors in its valuation.

The report also stated that, “Depending on the pace of NGS adoption in emerging diagnostic applications there could be significant upside to our outer year sales and EPS projections. Cancer diagnostics in the US could contribute ~$1.5-$2.0 Billion in revenues, by our calculations. High risk, prenatal testing globally could be another ~$1 Billion. Should these opportunities materialize, by 2018, ILMN's revenues could be significantly higher than the ~$3.2 Billion we currently project”.

Latest Ratings for ILMN

DateFirmActionFromTo
Oct 2019MaintainsHold
Oct 2019MaintainsOverweight
Oct 2019Initiates Coverage OnBuy

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Initiation Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NVDACascendMaintains240.0
NXTCBank of AmericaReiterates89.0
RNRJP MorganAssumes173.0
CARBNorthlandDowngrades23.0
GLIBACitiUpgrades80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Jefferies Mostly Positive On Retailers Ahead Of Earnings

UPDATE: Laidlow & Co. Initiates Coverage on Isis Pharmaceuticals, Inc. at Buy, Announces $52.00 PT